SCHEMBL21112925

SCHEMBL21112925

CC(=O)O[C@@H]1O[C@H](C(=O)N2CCN(c3ccccc3Cl)CC2)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.47
▸ AKR1C3 P42330 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ MAPK1 P28482 5/20 0.41
▸ LMNA P02545 3/20 0.41
▸ USP2 O75604 1/20 0.41
▸ MEN1 O00255 4/20 0.41
▸ KMT2A Q03164 4/20 0.41
▸ MAPT P10636 1/20 0.41
▸ POLB P06746 1/20 0.40
▸ GRM5 P41594 1/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ GLA P06280 1/20 0.39
▸ RBP4 P02753 1/20 0.39
▸ LIPE Q05469 1/20 0.39
▸ HTT P42858 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24145178 0.92 SMN1; SMN2 (0.42) GAAAKR1C3SMN1; SMN2MAPK1LMNA
SCHEMBL21112883 0.87 ALDH1A1 (0.53) AKR1C3SMN1; SMN2MAPK1LMNAMEN1
SCHEMBL20873345 0.85 TFPI2 (0.47) AKR1C3SMN1; SMN2LMNAUSP2MEN1
SCHEMBL20873315 0.83 MEN1 (0.50) AKR1C3SMN1; SMN2MAPK1LMNAMEN1
SCHEMBL24145067 0.80 ALDH1A1 (0.48) GAAAKR1C3MAPK1LMNAMEN1
SCHEMBL20873341 0.79 AKR1C3 (0.44) GAAAKR1C3SMN1; SMN2LMNAMEN1
SCHEMBL21112932 0.78 ALDH1A1 (0.51) GAAAKR1C3SMN1; SMN2MAPK1LMNA
SCHEMBL24145052 0.78 TFPI2 (0.42) AKR1C3SMN1; SMN2MAPK1LMNAMEN1
SCHEMBL20873248 0.78 ALDH1A1 (0.47) GAASMN1; SMN2LMNAMEN1KMT2A
SCHEMBL21112937 0.77 PPP5C (0.38) LMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 GAA 143/4885AKR1C3 1463/4885SMN1; SMN2 4049/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 GAA 143/4885AKR1C3 1463/4885SMN1; SMN2 4049/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 GAA 143/4885AKR1C3 1463/4885SMN1; SMN2 4049/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 GAA 143/4885AKR1C3 1463/4885SMN1; SMN2 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback